KRYS Krystal Biotech Inc.

54.41
+2.58  (+5%)
Previous Close 51.83
Open 51.74
Price To Book 4.53
Market Cap 941,749,500
Shares 17,308,390
Volume 146,655
Short Ratio
Av. Daily Volume 171,444
Stock charts supplied by TradingView

NewsSee all news

  1. Krystal Biotech Appoints Jennifer Chien as Chief Commercial Officer

    PITTSBURGH, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ:KRYS), a gene therapy company developing medicines to treat rare diseases, today announced the appointment of Jennifer Chien to the newly

  2. Krystal Biotech to Present at the Piper Jaffray 31st Annual Healthcare Conference

    PITTSBURGH, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., ("Krystal") (NASDAQ:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin

  3. Krystal Biotech Reports Third Quarter 2019 Financial and Operating Results

    Alignment With FDA on GMP Commercial Manufacturing Process for KB103 (Bercolagene telserpavec, "B-VEC")KB105 Granted Fast Track Designation by the FDAPlatform Patent for Delivering any Effector to the Skin Granted by

  4. Krystal Biotech Receives Positive EMA Opinion on Orphan Designation for KB105 to Treat Patients With TGM1 Deficient Autosomal Recessive Congenital Ichthyosis

    PITTSBURGH, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., ("Krystal") (NASDAQ:KRYS), a gene therapy company developing medicines to treat rare skin diseases, today announced that the European Medicines

  5. Krystal Biotech to Present at the Cantor 2019 Global Healthcare Conference and Chardan's 3rd Annual Genetic Medicines Conference

    PITTSBURGH, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., ("Krystal") (NASDAQ:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to commence 1H 2020.
KB103
Epidermolysis Bullosa
Phase 1/2 interim data due 1H 2020.
KB105
Transglutaminase-1 Deficient Autosomal Recessive Congenital Ichthyosis

Latest News

  1. Krystal Biotech Appoints Jennifer Chien as Chief Commercial Officer

    PITTSBURGH, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ:KRYS), a gene therapy company developing medicines to treat rare diseases, today announced the appointment of Jennifer Chien to the newly

  2. Krystal Biotech to Present at the Piper Jaffray 31st Annual Healthcare Conference

    PITTSBURGH, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., ("Krystal") (NASDAQ:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin

  3. Krystal Biotech Reports Third Quarter 2019 Financial and Operating Results

    Alignment With FDA on GMP Commercial Manufacturing Process for KB103 (Bercolagene telserpavec, "B-VEC")KB105 Granted Fast Track Designation by the FDAPlatform Patent for Delivering any Effector to the Skin Granted by

  4. Krystal Biotech Receives Positive EMA Opinion on Orphan Designation for KB105 to Treat Patients With TGM1 Deficient Autosomal Recessive Congenital Ichthyosis

    PITTSBURGH, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., ("Krystal") (NASDAQ:KRYS), a gene therapy company developing medicines to treat rare skin diseases, today announced that the European Medicines

  5. Krystal Biotech to Present at the Cantor 2019 Global Healthcare Conference and Chardan's 3rd Annual Genetic Medicines Conference

    PITTSBURGH, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., ("Krystal") (NASDAQ:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin

  6. Krystal Biotech Announces Granting of its First Foreign Patent and Reinforces its IP Portfolio with a New U.S. Patent

    PITTSBURGH, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., ("Krystal") (NASDAQ:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin

  7. Krystal Biotech Announces Initiation of Phase 1/2 Study of KB105 in Transglutaminase-1 ("TGM1") Deficient Autosomal Recessive Congenital Ichthyosis ("ARCI")

    PITTSBURGH, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., ("Krystal") (NASDAQ:KRYS), a gene therapy company developing medicines to treat rare skin diseases, today announced the initiation of the Phase 1/2

  8. Krystal Biotech Announces Attendance at Citi's 14th Annual Biotech Conference

    PITTSBURGH, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., ("Krystal") (NASDAQ:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin